Clinical Trial

Pancreatitis - Microbiome as Predictor of Severity II

Study acronym: P-MAPS II
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to evaluate the orointestinal microbiome and microbial derived metabolome in patients suffering from acute pancreatitis as a biomarker for severity. The main questions it aims to answer are: * Can the orointestinal microbiome robustly predict the course of acute pancreatitis? * How does the microbiome impact the severity of an acute pancreatitis? Buccal/ rectal swabs, plasma and stool is collected from patients with acute pancreatitis within 48h after hospital admission.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-17; most recent amendment 2025-07-10.
Trial Details
NCT Number NCT06508502
Lead Sponsor University Medical Center Goettingen
Conditions Acute Pancreatitis, Acute Pancreatitis With Infected Necrosis
Enrollment 700 participants
Start Date 2024-05-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-15